Business Context and Reporting Period
Akebia Therapeutics, Inc. (AKBA) filed a Form 8-K on November 30, 2020, reporting the execution of a material definitive agreement. The company is a biopharmaceutical firm headquartered in Cambridge, Massachusetts.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a lease amendment.
Material Changes and Agreement Details
On November 30, 2020, the Company executed the Sixth Amendment to its lease with CLPF-Cambridge Science Center, LLC regarding its headquarters and adjacent lab space.
- Property: Approximately 5,951 square feet of office, research, and laboratory space (Lab Space).
- Term Extension: Lease extended until January 31, 2025, with an option to extend through September 11, 2026.
- Rent: Monthly payment of $48,475.85 commencing December 1, 2021.
- Escalation: Annual rent increase of approximately 3% starting December 1, 2022.
- Improvements: Landlord contribution of up to $89,265.00 for leasehold improvements.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management commentary on future performance, or discussion of risks and contingencies beyond the terms of the lease amendment. The full text of the Sixth Amendment is expected to be filed as an exhibit to the Annual Report on Form 10-K for the fiscal year ending December 31, 2020.
Investor Verification Checklist
- Verify the total committed lease obligation through the initial extension date of January 31, 2025.
- Confirm the impact of the $89,265.00 landlord contribution on the company's capital expenditures and cash flow.
- Review the full Sixth Amendment exhibit in the upcoming Form 10-K for any additional covenants or termination clauses.
- Assess whether the 3% annual rent escalation aligns with the company's projected cash burn rate.